---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-000348"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:35:51.702750+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Trevi announces interim analysis for Phase 2 CANAL trial in Q1 2022, ends PRISM enrollment Jan 31

## Summary
- Phase 2 CANAL trial of Haduvio for chronic cough in IPF: interim statistical update planned Q1 2022 based on conditional power.
- Top-line data from CANAL expected H1 2022; interim may allow proof-of-concept before full enrollment.
- Phase 2b/3 PRISM trial for prurigo nodularis: enrollment ends Jan 31, 2022; top-line data H1 2022.
- Top-line data from both trials expected in first half of 2022.

## SEC filing metadata
- accession: 0001564590-22-000348
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022000348/0001564590-22-000348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022000348/trvi-8k_20220105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-000348
- JSON: https://secwatch.observer/filing/0001564590-22-000348.json
- Plain text: https://secwatch.observer/filing/0001564590-22-000348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.